Profile data is unavailable for this security.
About the company
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
- Revenue in CHF (TTM)6.73m
- Net income in CHF-58.53m
- Incorporated2004
- Employees168.00
- LocationMolecular Partners AGWagistrasse 14SCHLIEREN 8952SwitzerlandCHE
- Phone+41 447557700
- Fax+41 447557707
- Websitehttps://www.molecularpartners.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Santhera Pharmaceuticals Holding AG | 103.41m | 54.78m | 122.46m | 45.00 | -- | 1.83 | 2.12 | 1.18 | -13.81 | -13.81 | 17.07 | 5.30 | 1.19 | 3.37 | 63.72 | 2,298,089.00 | 63.20 | -33.83 | 137.60 | -52.61 | 96.87 | 86.74 | 52.97 | -79.38 | 0.7412 | 3.74 | 0.2644 | -- | 1,283.84 | 26.71 | 177.08 | -- | 1.87 | -- |
Newron Pharmaceuticals SpA | 8.63m | -15.45m | 182.37m | 23.00 | -- | -- | -- | 21.14 | -0.8659 | -0.8659 | 0.4834 | -1.60 | 0.2873 | -- | 4.57 | 375,041.10 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
Xlife Sciences AG | 988.44k | 14.88m | 183.65m | 17.00 | 26.44 | 0.6715 | 7.26 | 185.79 | 1.22 | 1.22 | 0.1382 | 47.95 | 0.002 | -- | 0.2044 | 58,143.53 | 1.85 | -- | 2.33 | -- | 45.43 | -- | 938.17 | -- | -- | -- | 0.1345 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
Molecular Partners AG | 6.73m | -58.53m | 218.63m | 168.00 | -- | 1.16 | -- | 32.50 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
Idorsia Ltd | 141.42m | -55.88m | 374.92m | 938.00 | -- | -- | -- | 2.65 | -0.3534 | -0.3534 | 0.7363 | -4.97 | 0.1912 | 0.1645 | 113.09 | 150,766.50 | -7.56 | -46.72 | -12.46 | -53.84 | 93.05 | -- | -39.51 | -709.80 | 1.00 | -26.26 | 5.82 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
Kuros Biosciences AG | 33.56m | -13.73m | 443.19m | 80.00 | -- | 7.74 | -- | 13.20 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 549.84m | 147.00 | 47.63 | -- | 45.63 | 3.49 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
Polypeptide Group AG | 309.39m | -48.99m | 1.08bn | 1.20k | -- | 2.96 | -- | 3.49 | -1.48 | -1.48 | 9.34 | 11.01 | 0.5137 | 2.31 | 5.08 | 257,397.70 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
Data as of Jun 14 2024. Currency figures normalised to Molecular Partners AG's reporting currency: Swiss Franc CHF
41.52%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 17 Nov 2023 | 8.70m | 23.71% |
Suvretta Capital Management LLCas of 31 Dec 2023 | 1.75m | 4.77% |
UBS Asset Management Switzerland AGas of 04 Jun 2024 | 1.15m | 3.14% |
EcoR1 Capital, LLCas of 17 Nov 2023 | 1.09m | 2.96% |
GAM Investment Management (Switzerland) AGas of 21 Nov 2022 | 1.07m | 2.91% |
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 483.42k | 1.32% |
Union Bancaire Priv�e, UBP SAas of 31 Jan 2024 | 417.70k | 1.14% |
Z�rcher Kantonalbank (Investment Management)as of 30 Apr 2024 | 292.11k | 0.80% |
ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 31 Mar 2024 | 199.97k | 0.55% |
Pictet Asset Management SAas of 29 Feb 2024 | 83.92k | 0.23% |
More ▼
Data from 31 Jan 2024 - 31 May 2024Source: FactSet Research Systems Inc.